Abstract
Among young persons, ease of use, high efficacy, and high acceptability makes the
etonogestrel contraceptive implant an important choice for this age group. Adolescent-friendly,
patient-centered counseling considers the patient's cognitive development, the influence
of friends and family, as well as their own preferences and values. Age-appropriate
language, graphics, and models are useful to explain contraceptive options and relevant
side effects. Effectiveness, reversibility, safety, noncontraceptive benefits, and
side effects are important attributes and should be discussed when teens are choosing
a contraceptive method. In this review we describe suggested best practices for counseling
adolescents about the etonogestrel implant so they can make informed, prudent decisions
about using this contraceptive method.
Key Words
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Journal of Pediatric and Adolescent GynecologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- FPA fact sheet. Contraception: past, present and future.(Available:)http://www.fpa.org.uk/sites/default/files/contraception-past-present-and-future-factsheet-november-2010.pdfDate accessed: January 5, 2020
- Tolerability and clinical safety of Implanon.Eur J Contracept Reprod Health Care. 2008; 13: 29
- Nexplanon®: what Implanon® did next.J Fam Plan Reprod Health Care. 2011; 36: 187
- The US etonogestrel implant mandatory clinical training and active monitoring programs: 6-year experience.Contraception. 2017; 95: 205
- Neurovascular anatomy of the adult female medial arm in relationship to potential sites for insertion of the etonogestrel contraceptive implant.Contraception. 2019; 100: 26
- US Food and Drug Administration: Merck and Co I. Highlights of prescribing information.(Available:)https://www.merck.com/product/usa/pi_circulars/n/nexplanon/nexplanon_pi.pdfDate accessed: February 12, 2020
- Letters to HCPs. Nexplanon 68 mg implant UK DHPC 15-Jan-2020. Direct healthcare professional communication on the association of Nexplanon – etonogestrel 68 mg, implant for subdermal use. Update to the insertion and removal instructions to minimise the risks of neurovascular injury and implant migration.(Available:)https://www.medicines.org.uk/emc/dhpc/1662/DocumentDate accessed: February 10, 2020
- Two year continuation rates of contraceptive methods in France: a cohort study from the French national health insurance database.Eur J Contracept Reprod Health Care. 2018; 23: 421
- Long-acting reversible contraception in adolescents: a systematic review and meta-analysis.Am J Obstet Gynecol. 2017; 216: 364.e1
- Continuation of reversible contraception in teenagers and young women.Obstet Gynecol. 2012; 120: 1298
- Provision of no-cost, long-acting contraception and teenage pregnancy.N Engl J Med. 2014; 371: 1316
- Conceptions in England and Wales.(Available:)https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/conceptionandfertilityrates/bulletins/conceptionstatistics/2018Date: 2018Date accessed: March 25, 2020
- Association between long-acting reversible contraceptive use, teenage pregnancy, and abortion rates in England.Int J Womens Health. 2014; 6: 961
- Implanon as a contraceptive choice for teenage mothers: a comparison of contraceptive choices, acceptability and repeat pregnancy.Contraception. 2010; 81: 421
- Why is the teen birth rate falling?.(Available:)https://www.pewresearch.org/fact-tank/2019/08/02/why-is-the-teen-birth-rate-fallingDate accessed: April 17, 2020
- Factors associated with contraceptive method choice and initiation in adolescents and young women.J Adolesc Health. 2017; 61: 454
- Urban adolescents’ and young adults’ decision-making process around selection of intrauterine contraception.J Pediatr Adolesc Gynecol. 2016; 29: 234
- Identifying counseling needs of nulliparous adolescent intrauterine contraceptive users: a qualitative approach.J Adolesc Health. 2013; 52: 293
- Client preferences for contraceptive counseling: a systematic review.Am J Prev Med. 2018; 55: 691
- The role of the social network in contraceptive decision-making among young, African American and Latina Women.J Adolesc Health. 2010; 47: 374
- Familiarity and acceptability of long-acting reversible contraception and contraceptive choice.Am J Obstet Gynecol. 2020; 222: S884.e1
- Young women’s contraceptive decision making: do preferences for contraceptive attributes align with method choice?.Perspect Sex Reprod Health. 2016; 48: 119
- Women’s perceptions and reasons for choosing the pill, patch, or ring in the CHOICE study: a cross-sectional survey of contraceptive method selection after counseling.BMC Womens Health. 2013; 13: 9
- Motivations for interest, disinterest and uncertainty in intrauterine device use among young women.Matern Child Health J. 2017; 21: 1753
- Fear of intrauterine contraception among adolescents in New York City.Contraception. 2014; 89: 446
- Young women’s attitudes towards, and experiences of, long-acting reversible contraceptives.Eur J Contracept Reprod Health Care. 2014; 19: 276
- A qualitative study of young women’s beliefs about intrauterine devices: fear of infertility.J Midwifery Womens Health. 2016; 61: 482
- “Just wear dark underpants mainly”: Learning from adolescents’ and young adults’ experiences with early discontinuation of the contraceptive implant.J Pediatr Adolesc Gynecol. 2017; 30: 395
- Planned Parenthood League of Massachusetts: Protection methods demonstration kit.(Available:)
- Power to Decide: Educational materials.(Available:)https://shop.powertodecide.org/educational-materials.htmlDate accessed: May 6, 2020
- Counseling adolescents about contraception: towards the development of an evidence-based protocol for contraceptive counselors.J Adolesc Health. 2013; 52: S6
- Women’s values in contraceptive choice: a systematic review of relevant attributes included in decision aids.BMC Womens Health. 2014; 14: 28
- The role of contraceptive attributes in women’s contraceptive decision making.Am J Obstet Gynecol. 2015; 213: 46.e1
- Jensen J. Creinin M.D. Speroff and Darney’s Clinical Guide to Contraception. 6th. Wolters Kluwer, New York2019: 15
- A 3-year multicentre randomized controlled trial of etonogestrel-and levonorgestrel-releasing contraceptive implants, with non-randomized matched copper-intrauterine device controls.Hum Reprod. 2015; 30: 2527
- Safety and efficacy of a single-rod etonogestrel implant (Implanon): results from 11 international clinical trials.Fertil Steril. 2009; 91: 1646
- Fertility after discontinuation of contraception: a comprehensive review of the literature.Contraception. 2011; 84: 465
- Return of fertility after discontinuation of contraception: a systematic review and meta-analysis.Contracept Reprod Med. 2018; 3: 9
- Is previous aberrant reproductive outcome predictive of subsequently reduced fecundity?.Hum Reprod. 2004; 20: 657
- The return of fertility after discontinuation of oral contraception in Malaysian women.Med J Malaysia. 1994; 49: 348
- U.S. medical eligibility criteria for contraceptive use, 2016.MMWR Recomm Rep. 2016; 65: 1
- Etonogestrel implant in adolescents: evaluation of clinical aspects.Contraception. 2011; 83: 336
- Steroidal contraceptives: effect on carbohydrate metabolism in women without diabetes mellitus.Cochrane Database Syst Rev. 2012; 4: CD006133
- Association between progestin-only contraceptive use and cardiometabolic outcomes: a systematic review and meta-analysis.Eur J Prev Cardiol. 2018; 25: 1042
- The effects of Implanon® on menstrual bleeding patterns.Eur J Contracept Reprod Health Care. 2008; 13: 13
- Control of endometriosis-associated pain with etonogestrel-releasing contraceptive implant and 52-mg levonorgestrel-releasing intrauterine system: randomized clinical trial.Fertil Steril. 2018; 110: 1129
- Implanon® versus medroxyprogesterone acetate: effects on pain scores in patients with symptomatic endometriosis - a pilot study.Contraception. 2009; 79: 29
- Can initial vaginal bleeding patterns in etonogestrel implant users predict subsequent bleeding in the first 2 years of use?.Contraception. 2019; 100: 264
- There might be blood: a scoping review on women’s responses to contraceptive-induced menstrual bleeding changes.Reprod Health. 2018; 15: 114
- Patients’ perspectives about why they have their contraceptive Implanon NXT device removed early.Aust Fam Physician. 2016; 45: 740
- Prevalence of early discontinuation and associated factors among a retrospective cohort of etonogestrel contraceptive implant users.Eur J Contracept Reprod Health Care. 2019; 24: 475
- Twelve-month discontinuation of etonogestrel implant in an outpatient pediatric setting.Contraception. 2016; 94: 81
- Predictors of discontinuation of long-acting reversible contraception before 30 months of use by adolescents and young women.J Adolesc Health. 2019; 65: 295
- Continuation rates of Implanon® in the UK: data from an observational study in a clinical setting.Contraception. 2006; 74: 287
- Weight change at 12 months in users of three progestin-only contraceptive methods.Contraception. 2013; 88: 503
- Body composition and bone mineral density in users of the etonogestrel-releasing contraceptive implant.Arch Gynecol Obstet. 2015; 292: 1387
- Assessing weight status in adolescent and young adult users of the etonogestrel contraceptive implant.J Pediatr Adolesc Gynecol. 2019; 32: 409
- Patterns of weight change and their relation to diet in a cohort of healthy women.Am J Clin Nutr. 1990; 51: 1100
- A multicenter randomized clinical trial of etonogestrel and levonorgestrel contraceptive implants with nonrandomized copper intrauterine device controls: effect on weight variations up to 3 years after placement.Contraception. 2018; 98: 181
- A three-year comparative study of continuation rates, bleeding patterns and satisfaction in Australian women using a subdermal contraceptive implant or progestogen releasing-intrauterine system.Eur J Contracept Reprod Health Care. 2014; 19: 5
- The relationship between progestin hormonal contraception and depression: a systematic review.Contraception. 2018; 97: 478
- Subcutaneous DMPA vs. intramuscular DMPA: a 2-year randomized study of contraceptive efficacy and bone mineral density.Contraception. 2009; 80: 7
- Effect of the subdermal contraceptive etonogestrel implant (Implanon®) on biochemical and hormonal parameters (three years follow-up).Eur J Contracept Reprod Health Care. 2008; 13: 238
- A prospective study of the forearm bone density of users of etonorgestrel- and levonorgestrel-releasing contraceptive implants.Hum Reprod. 2006; 21: 466
- A three-year longitudinal evaluation of the forearm bone density of users of etonogestrel- and levonorgestrel-releasing contraceptive implants.Reprod Health. 2007; 4: 11
- Bone mineral density during long-term use of the progestagen contraceptive implant Implanon® compared to a non-hormonal method of contraception.Hum Reprod. 2000; 15: 118
- Ovarian function during the use of a single contraceptive implant: Implanon compared with Norplant.Fertil Steril. 1998; 69: 714
- Ovarian cysts in users of Implanon® and Jadelle® subdermal contraceptive implants.Contraception. 2006; 73: 532
- Etonogestrel implant migration to the vasculature, chest wall, and distant body sites: cases from a pharmacovigilance database.Contraception. 2017; 96: 439
- Difficult removal of subdermal contraceptive implants: a multidisciplinary approach involving a peripheral nerve expert.Contraception. 2017; 96: 89
- Referral center experience with nonpalpable contraceptive implant removals.Obstet Gynecol. 2019; 134: 801
Article info
Publication history
Published online: July 01, 2020
Footnotes
Dr Berlan is a Merck Nexplanon Clinical Trainer and Consultant to Merck, Bayer, and Ohio Chapter, American Academy of Pediatrics, and a reviewer for UptoDate (royalties received). Dr Richards is a Merck Nexplanon Clinical Trainer and Consultant to Merck. Dr Sales Vieira serves on Medical Advisory Boards and gives lectures for Bayer and Merck. Dr Kaunitz is a Consultant for Merck and Mithra, and an author for UpToDate (royalties received). His institution receives research monies from Abbvie, Merck, and Mithra, and has received travel reimbursement from American College of Obstetricians and Gynecologists and the Centers for Disease Control and Prevention for preparation of guidance regarding contraception and menopause. Dr Edelman is a consultant for Gynuity Health Projects, FHI360, and Nexplanon trainer for Merck (no monies accepted since 2016), and an author for UptoDate (royalties received). Her institution receives research monies from Merck, HRA Pharma, and the National Institutes of Health on projects for which she is principal investigator. These potential conflicts have been reviewed and managed by Oregone Health & Science University. She is the Chair of the American College of Obstetricians and Gynecologists Practice Bulletins for Gynecology committee and has received travel and honoraria from the American College of Obstetricians and Gynecologists. She is an expert technical consultant for the Centers for Disease Control and Prevention and the World Health Organization on reproductive health issues and has received travel reimbursement. Dr Creinin serves on an Advisory Board for Merck & Co and TherapeuticsMD, and is a consultant for Danco, Estetra Mayne, Medicines360, and Merck & Co. The Department of Obstetrics and Gynecology, University of California, Davis, receives research funding for contraceptive research from Daré, HRA Pharma, Medicines360, Merck & Co, and Sebela. Dr Mansour has served on an advisory board for Merck & Co, manufacturer of the etonogestrel implant, and has received financial support to attend pharmaceutical advisory board meetings, undertake research studies, speak at educational meetings, webinars, and conferences, along with travel grants from Bayer, Consilient Healthcare, Gedeon, Merck & Co, Mithra, Mylan, Pfizer, and Vifor Pharma. Dr Fraser indicated no conflicts of interest.
Identification
Copyright
© 2020 North American Society for Pediatric and Adolescent Gynecology. Published by Elsevier Inc.
